Premium
Serum NT ‐pro CNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia
Author(s) -
Kubota Takuo,
Wang Wei,
Miura Kohji,
Nakayama Hirofumi,
Yamamoto Keiko,
Fujiwara Makoto,
Ohata Yasuhisa,
Tachibana Makiko,
Kitaoka Taichi,
Takakuwa Satoshi,
Miyoshi Yoko,
Namba Noriyuki,
Ozono Keiichi
Publication year - 2016
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.13025
Subject(s) - medicine , achondroplasia , endocrinology , short stature , biomarker , idiopathic short stature , natriuretic peptide , hormone , growth hormone , biology , pediatrics , heart failure , biochemistry
Summary Objective Serum amino‐terminal propeptide of C‐type natriuretic peptide ( NT ‐pro CNP ) levels have been proposed as a biomarker of linear growth in healthy children. The usefulness of NT ‐pro CNP in patients with achondroplasia ( ACH )/hypochondroplasia ( HCH ) remains to be elucidated. The objective was to study whether serum NT ‐pro CNP level is a good biomarker for growth in ACH / HCH and other patients of short stature. Design This was a longitudinal cohort study. Patients Sixteen children with ACH (aged 0·4–4·3 years), six children with HCH (2·7–6·3 years), 23 children with idiopathic short stature ( ISS ) (2·2–9·0 years), eight short children with GH deficiency ( GHD ) (2·9–6·8 years) and five short children born small for gestational age ( SGA ) (2·0–6·6 years). Patients with ACH / HCH received GH treatment for 1 year. Measurements Serum NT ‐pro CNP levels and height were measured. Results NT ‐pro CNP levels positively correlated with height velocity in these short children ( P < 0·05, r = 0·27). NT ‐pro CNP levels inversely correlated with age in children with ISS alone ( P < 0·01, r = −0·55). Serum NT ‐pro CNP levels in patients with ACH / HCH were increased 3 months following the initiation of GH treatment ( P < 0·05). Height SDS gain during GH treatment for 1 year was positively correlated with the changes in NT ‐pro CNP levels after the initiation of GH ( P < 0·01, r = 0·72). Conclusion Serum NT ‐pro CNP levels may be a good biomarker to indicate the effect of GH treatment on growth in patients with ACH / HCH at least in the first year and height velocity in short stature patients.